Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Thoa Thi Kim,Nguyen ^[1] ; Seon Min,Woo ^[2] ; Seung Un,Seo ^[2] ; Asmita,Banstola ^[3] ; Haesoo,Kim ^[4] ; Ramesh,Duwa ^[5] ; An Thi Thanh,Vu ^[4] ; In-Sun,Hong ^[6] ; Taeg Kyu,Kwon ^[7] ; Simmyung,Yook ^[8]

作者单位： College of Pharmacy, Keimyung University, Daegu, 42602, Republic of Korea; Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea. ^[1] Department of Immunology, School of medicine, Keimyung University, Daegu, Republic of Korea. ^[2] Department of Dermatology, Harvard Medical School, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA. ^[3] College of Pharmacy, Keimyung University, Daegu, 42602, Republic of Korea. ^[4] Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea; Department of Radiology, Molecular Imaging Program at Stanford (MIPS), School of medicine, Stanford University, Stanford, CA, 94305, USA. ^[5] Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, 406-840, Republic of Korea. ^[6] Department of Immunology, School of medicine, Keimyung University, Daegu, Republic of Korea; Center for Forensic Pharmaceutical Science, Keimyung University, Daegu, 42601, Republic of Korea. Electronic address: kwontk@dsmc.or.kr. ^[7] Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea; School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. Electronic address: ysimmyung@skku.edu. ^[8]

关键词 Odanacatib Resistant cancer Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)poly(lactic-co-glycolic) nanoparticles